1. Home
  2. MNKD vs MFIC Comparison

MNKD vs MFIC Comparison

Compare MNKD & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNKD
  • MFIC
  • Stock Information
  • Founded
  • MNKD 1991
  • MFIC 2004
  • Country
  • MNKD United States
  • MFIC United States
  • Employees
  • MNKD N/A
  • MFIC N/A
  • Industry
  • MNKD Biotechnology: Pharmaceutical Preparations
  • MFIC Finance/Investors Services
  • Sector
  • MNKD Health Care
  • MFIC Finance
  • Exchange
  • MNKD Nasdaq
  • MFIC Nasdaq
  • Market Cap
  • MNKD 1.4B
  • MFIC 1.2B
  • IPO Year
  • MNKD 2004
  • MFIC 2004
  • Fundamental
  • Price
  • MNKD $4.15
  • MFIC $13.13
  • Analyst Decision
  • MNKD Strong Buy
  • MFIC Buy
  • Analyst Count
  • MNKD 5
  • MFIC 6
  • Target Price
  • MNKD $9.40
  • MFIC $13.60
  • AVG Volume (30 Days)
  • MNKD 1.9M
  • MFIC 348.4K
  • Earning Date
  • MNKD 05-08-2025
  • MFIC 05-12-2025
  • Dividend Yield
  • MNKD N/A
  • MFIC 11.58%
  • EPS Growth
  • MNKD 228.27
  • MFIC N/A
  • EPS
  • MNKD 0.10
  • MFIC 1.22
  • Revenue
  • MNKD $297,595,000.00
  • MFIC $312,149,000.00
  • Revenue This Year
  • MNKD $14.36
  • MFIC $10.59
  • Revenue Next Year
  • MNKD $13.36
  • MFIC $0.76
  • P/E Ratio
  • MNKD $40.01
  • MFIC $10.77
  • Revenue Growth
  • MNKD 32.50
  • MFIC 12.66
  • 52 Week Low
  • MNKD $4.05
  • MFIC $10.18
  • 52 Week High
  • MNKD $7.63
  • MFIC $16.37
  • Technical
  • Relative Strength Index (RSI)
  • MNKD 37.04
  • MFIC 64.97
  • Support Level
  • MNKD $4.07
  • MFIC $12.50
  • Resistance Level
  • MNKD $4.25
  • MFIC $13.17
  • Average True Range (ATR)
  • MNKD 0.16
  • MFIC 0.26
  • MACD
  • MNKD -0.03
  • MFIC 0.05
  • Stochastic Oscillator
  • MNKD 12.82
  • MFIC 95.36

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

Share on Social Networks: